Gufic Biosciences · NSE: GUFICBIO · BSE: 509079
Q2 FY21 results · Jul–Sep 2020
Gufic Biosciences reported revenue from operations of ₹120.35 crore (up 39.9% from Q2 FY20) and net profit of ₹16.33 crore (up 279.5% from Q2 FY20) for Q2 FY21 (Jul–Sep 2020), on a standalone basis.
| Item | Q2 FY21 | Q2 FY20 | YoY | Q1 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 120.35 | 86.03 | +39.9% | 54.14 | +122.3% |
| Other income | 2.25 | 1.61 | +39.9% | 0.99 | +127.7% |
| Total income | 122.60 | 87.64 | +39.9% | 55.13 | +122.4% |
| Profit before tax | 22.01 | 5.65 | +289.5% | (5.11) | Turned profit |
| Net profit for the period | 16.33 | 4.30 | +279.5% | (3.75) | Turned profit |
| EPS, basic (₹) | 2.10 | 0.55 | +281.8% | (0.48) | Turned profit |
| Net margin (%) | 13.6 | 5.0 | -6.9 |
Standalone
- Filed with BSE
- 17 Nov 2020, 14:48 IST
- Board meeting
- 12 Nov 2020
- Period
- 01 Jul 2020 to 30 Sep 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE